← Leaderboards
Jia Zhou
University Of Texas Med Br Galveston
$10,435,378
Attributed
$22,893,597
Total exposure
16
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,893,597 · 16
By mechanism
R01$17,768,104 · 6
R43$1,764,167 · 4
R61$1,573,491 · 1
R21$1,313,835 · 3
U18$474,000 · 2
Top collaborators
- Kathryn A. Cunningham17 shared
- Eric J Nestler12 shared
- Gabrielle Rudenko12 shared
- Fernanda Laezza6 shared
- Alfred J Robison6 shared
- Xiaodong Cheng3 shared
- Jai Rudra3 shared
- John A Allen2 shared
Most similar at University Of Texas Med Br Galveston
Same institution · by research overlap
- Fernanda Laezza$9,952,566
- Jun-Ho La$2,269,431
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsIn VivoSmall MoleculeDesignBehavioralBrainResponseIn VitroLeadBaseInnovationBindingAddictionBehaviorPharmacologyCellsPre-ClinicalAnimal ModelCocaineMediatingLigandsSitePublic HealthDose
Grant awards (52)
Discovery of GPR52 ligand probes for cocaine use disorder$795,090
R01 · FY2025 · DA
Probing brain circuit and behavior with protein:protein interaction modulators$794,232
R01 · FY2025 · MH
Small molecule modulators of ÎFosB$609,024
R01 · FY2025 · DA
5-HT2 Receptor Allosterism in Cocaine Use Disorder$538,887
R01 · FY2025 · DA · contact PI
Nanoparticle-encapsulated Epigenetic Inhibitors for Treatment of Inflammatory Bowel Diseases$192,543
R21 · FY2025 · AI
Probing brain circuit and behavior with protein:protein interaction modulators$794,232
R01 · FY2024 · MH
Small molecule modulators of ÎFosB$614,032
R01 · FY2024 · DA
5-HT2 Receptor Allosterism in Cocaine Use Disorder$538,887
R01 · FY2024 · DA · contact PI
Nanoparticle-encapsulated Epigenetic Inhibitors for Treatment of Inflammatory Bowel Diseases$237,920
R21 · FY2024 · AI
Probing brain circuit and behavior with protein:protein interaction modulators$824,232
R01 · FY2023 · MH
Small molecule modulators of ÎFosB$621,544
R01 · FY2023 · DA
5-HT2 Receptor Allosterism in Cocaine Use Disorder$538,887
R01 · FY2023 · DA · contact PI
Developing GPR37 activators as non-opioid pain therapeutics$1,573,491
R61 · FY2022 · NS
Small molecule modulators of ÎFosB$625,300
R01 · FY2022 · DA
5-HT2 Receptor Allosterism in Cocaine Use Disorder$537,543
R01 · FY2022 · DA · contact PI
Leveraging ÎFosB as a potential therapeutic for Alzheimer's Disease$458,330
R01 · FY2022 · DA
Small molecule modulators of ÎFosB$658,323
R01 · FY2021 · DA
Small molecule modulators of ÎFosB function$609,848
R01 · FY2020 · DA
BRD4 Inhibition for Opioid Pharmacotherapy$237,000
U18 · FY2020 · DA
AMPAkines for Novel Opioid Use Disorder Pharmacotherapy$237,000
U18 · FY2020 · DA
Small molecule modulators of ÎFosB function$611,917
R01 · FY2019 · DA
5âHT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER$477,285
R01 · FY2019 · DA · contact PI
5âHT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER$107,146
R01 · FY2019 · DA · contact PI
Small molecule modulators of ÎFosB function$618,125
R01 · FY2018 · DA
Discovery of Chemical Probes for Psychiatric Disorders and Addiction$562,032
R01 · FY2018 · MH
5âHT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER$477,285
R01 · FY2018 · DA · contact PI
Small molecule modulators of ÎFosB Function$406,596
R01 · FY2018 · DA
5-HT2CR Allosteric Modulators as Novel Pharmacotherapy in Cocaine Use Disorder$107,090
R01 · FY2018 · DA · contact PI
Small molecule modulators of ÎFosB function$621,574
R01 · FY2017 · DA
Discovery of Chemical Probes for Psychiatric Disorders and Addiction$548,917
R01 · FY2017 · MH
5âHT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER$477,285
R01 · FY2017 · DA · contact PI
5âHT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER$8,467
R01 · FY2017 · DA · contact PI
Small molecule modulators of ÎFosB function$635,178
R01 · FY2016 · DA
Discovery of Chemical Probes for Psychiatric Disorders and Addiction$518,312
R01 · FY2016 · MH
5âHT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER$510,641
R01 · FY2016 · DA · contact PI
5âHT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER$8,899
R01 · FY2016 · DA · contact PI
5âHT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER$436,045
R01 · FY2015 · DA · contact PI
Novel Pharmacological Probes Targeting Exchange Proteins Activated by cAMP (EPAC)$308,233
R01 · FY2015 · GM
Synthetic Nanofiber Vaccines for Cocaine Addiction$7,927
R21 · FY2015 · DA
Novel Pharmacological Probes Targeting Exchange Proteins Activated by cAMP (EPAC)$277,625
R01 · FY2014 · GM
Synthetic Nanofiber Vaccines for Cocaine Addiction$232,500
R21 · FY2014 · DA
Novel Pharmacological Probes Targeting Exchange Proteins Activated by cAMP (EPAC)$491,061
R01 · FY2013 · GM
Optimization of Allosteric Modulators of 5-HT2C Receptor$220,320
R21 · FY2013 · MH · contact PI
Synthetic Nanofiber Vaccines for Cocaine Addiction$193,125
R21 · FY2013 · DA
Optimization of Allosteric Modulators of 5-HT2C Receptor$229,500
R21 · FY2012 · MH · contact PI
NAAG Peptidase Inhibitors for the Treatment of Traumatic Brain Injury$379,412
R43 · FY2008 · NS · contact PI
Prodrugs of NAAG Peptidase Inhibitors for the Treatment of Schizophrenia$319,887
R43 · FY2008 · MH · contact PI
Development of GSK-3 Beta Inhibitors for the Treatment of Parkinson's Disease$282,300
R43 · FY2008 · NS · contact PI
Piperidine-Based Compounds as Therapeutics for Narcolepsy-Cataplexy$250,000
R43 · FY2008 · MH · contact PI
Development of GSK-3 Beta Inhibitors for the Treatment of Parkinson's Disease$282,568
R43 · FY2007 · NS · contact PI
Piperidine-Based Compounds as Therapeutics for Narcolepsy-Cataplexy$212,011
R43 · FY2007 · MH · contact PI
Piperidine-Based Compounds as Therapeutics for Narcolepsy-Cataplexy$37,989
R43 · FY2007 · MH · contact PI